Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Crescent Biopharma, Inc. (CBIO)
USD15.06
-0.25 (-1.60%)
US NASDAQ Healthcare Biotechnology
Address
300 Fifth Avenue 2451
Waltham, MA, US
Waltham, MA, US
CEO
Joshua T. Brumm
Website
crescentbiopharma.com
IPO
2014-01-10
CIK 1253689 ISIN KYG2545C1042
Also trades on
NASDAQ Capital Market · CBIO (USD)
NASDAQ Global Market · GLYC (USD)
Description
Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., focusing on the joint advancement and commercialization of oncology therapeutics, encompassing innovative combination approaches. The company's operations are headquartered in Waltham, Massachusetts.
Market Cap & Enterprise Value
Merger & Acquisition History
| Target company | Ticker | Date | Filing |
|---|---|---|---|
| Targacept | TRGT | 2015-05-22 | View |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD15.06
-0.25 (-1.60%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
315.6K
Beta
1.19
Float Shares
21.31M
Free Float %
77.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.32% | +2.73% | +1.60% | +100.00% | +41.46% | +55.65% | -28.12% | -90.39% | -91.80% | -97.02% | -97.95% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (13 ratings, all time)
Buy
Price Targets & DCF
Current price
15.06
Low
29.00
+92.6%
Consensus
33.00
+119.1%
Median
35.00
+132.4%
High
35.00
+132.4%
DCF (Unlevered)
20.86
+38.5%
DCF (Levered)
19.90
+32.2%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 8 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 1 |
29.00
+92.6%
|
| Last Year | 5 |
31.40
+108.5%
|
| All Time | 5 |
31.40
+108.5%
|
Quality scores
Altman Z-Score
16.34
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
4 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-955.7% Q1'26: +10.3% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-1,542.9% Q1'26: -874.3% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-1,381.0% Q1'26: -2,240.9% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: +2,468.4% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-46.6% ★ Q1'26: +55.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.01× Q1'26: -0.02× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2006 actual |
Dec 2007 actual |
Dec 2008 actual |
Dec 2009 actual |
Dec 2010 actual |
Dec 2011 actual |
Dec 2012 actual |
Dec 2013 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 5 EPS Ana. |
Dec 2027 4 Rev. Ana. 4 EPS Ana. |
Dec 2028 6 Rev. Ana. 5 EPS Ana. |
Dec 2029 5 Rev. Ana. 1 EPS Ana. |
Dec 2030 3 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
8.38M
est.
|
8.61M
est.
|
28.29M
est.
|
36.30M
est.
|
51.08M
est.
|
3.81M
est: 104.29M (-96.3%)
|
15.26M
est: 114.45M (-86.7%)
|
3.99M
est: 5.10M (-21.8%)
|
10.16M
est: 10.00M (+1.6%)
|
1.16M
est: 835.5K (+38.8%)
|
75.0K
est: 66.7K (+12.5%)
|
—
|
10.84M
est: 7.50M (+44.6%)
|
1.82M
1.77M – 1.84M
-75.7% YoY
|
5.58M
5.34M – 6.98M
+206.4% YoY
|
8.20M
7.84M – 10.26M
+46.9% YoY
|
16.73M
16.01M – 20.93M
+104.1% YoY
|
76.89M
73.55M – 96.18M
+359.5% YoY
|
| EBITDA |
-5.03M
est.
|
-85.39M
est.
|
-30.46M
est.
|
-30.92M
est.
|
35.09M
est.
|
-6.00M
est: 81.53M (-107.4%)
|
3.73M
est: 2.33M (+60.2%)
|
-10.47M
est: -48.59M (+78.4%)
|
-51.24M
est: -6.00M (-754.0%)
|
-63.18M
est: -501.3K (-12,503.8%)
|
-47.20M
est: -40.0K (-117,889.3%)
|
-44.17M
|
-149.67M
est: -4.50M (-3,226.1%)
|
-1.09M
-1.10M – -1.06M
+75.7% YoY
|
-3.35M
-4.19M – -3.20M
-206.4% YoY
|
-4.92M
-6.15M – -4.71M
-46.9% YoY
|
-10.04M
-12.56M – -9.60M
-104.1% YoY
|
-46.13M
-57.71M – -44.13M
-359.5% YoY
|
| EBIT |
-5.03M
est.
|
-100.28M
est.
|
-35.95M
est.
|
-34.67M
est.
|
25.15M
est.
|
-6.08M
est: 71.42M (-108.5%)
|
3.63M
est: -1.79M (+302.8%)
|
-10.61M
est: -49.45M (+78.5%)
|
-51.51M
est: -6.00M (-758.5%)
|
-63.45M
est: -501.3K (-12,556.5%)
|
-47.40M
est: -40.0K (-118,407.2%)
|
-44.21M
|
-149.76M
est: -4.50M (-3,227.9%)
|
-1.09M
-1.10M – -1.06M
+75.7% YoY
|
-3.35M
-4.19M – -3.20M
-206.4% YoY
|
-4.92M
-6.15M – -4.71M
-46.9% YoY
|
-10.04M
-12.56M – -9.60M
-104.1% YoY
|
-46.13M
-57.71M – -44.13M
-359.5% YoY
|
| Net Income |
20.98M
est.
|
-88.08M
est.
|
-32.77M
est.
|
-33.51M
est.
|
22.34M
est.
|
-6.11M
est: 74.60M (-108.2%)
|
3.66M
est: -509.5K (+817.6%)
|
-10.61M
est: -48.87M (+78.3%)
|
-51.03M
est: -6.98B (+99.3%)
|
-63.43M
est: -8.04B (+99.2%)
|
-46.69M
est: -5.61B (+99.2%)
|
-48.52M
est: -3.29B (+98.5%)
|
-153.94M
est: -107.69M (-42.9%)
|
-32.85M
-35.59M – -30.11M
+69.5% YoY
|
-36.30M
-44.24M – -28.37M
-10.5% YoY
|
-36.00M
-45.06M – -26.94M
+0.8% YoY
|
-38.95M
-51.65M – -36.75M
-8.2% YoY
|
-35.61M
-47.23M – -33.60M
+8.6% YoY
|
| SGA |
3.68B
est.
|
3.78B
est.
|
8.33M
est.
|
10.01M
est.
|
23.27M
est.
|
2.10M
est: 33.90M (-93.8%)
|
2.18M
est: 15.25M (-85.7%)
|
2.90M
est: 2.24B (-99.9%)
|
16.74M
est: 4.39B (-99.6%)
|
17.12M
est: 366.48M (-95.3%)
|
19.09M
est: 29.24M (-34.7%)
|
16.32M
|
25.39M
est: 3.29B (-99.2%)
|
799.56M
776.28M – 807.33M
-75.7% YoY
|
2.45B
2.34B – 3.06B
+206.4% YoY
|
3.60B
3.44B – 4.50B
+46.9% YoY
|
7.34B
7.02B – 9.18B
+104.1% YoY
|
33.74B
32.27B – 42.20B
+359.5% YoY
|
| EPS |
-101.59
est.
|
-129.74
est.
|
-194.14
est.
|
-122.60
est.
|
18.75
est.
|
-5.11
est: -134.06 (+96.2%)
|
3.06
est: -87.20 (+103.5%)
|
-8.87
est: -165.73 (+94.6%)
|
-1.12
est: -108.20 (+99.0%)
|
-1.23
est: -124.75 (+99.0%)
|
-0.89
est: -87.00 (+99.0%)
|
-1.40
est: -51.00 (+97.3%)
|
-14.78
est: -10.26 (-44.1%)
|
-3.20
-3.42 – -2.89
+68.8% YoY
|
-3.25
-4.25 – -2.72
-1.5% YoY
|
-3.46
-4.33 – -2.59
-6.7% YoY
|
-3.74
-4.96 – -3.53
-8.0% YoY
|
-3.42
-4.54 – -3.23
+8.6% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-08 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-32.09M
OE per share TTM
-6.19
Owner's Yield
-5.70%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
56.4%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
3
Total invested
189.4K
Insider transactions (90d)
0
Beneficial owners (>5%)
45
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | GNI Group Ltd. | 73.31M | 85.36% | — | 73.31M | — | 10.00 | CO | Japan | 2023-11-01 | ↗ |
| 2 | GNI USA, Inc. | 73.31M | 85.36% | — | 73.31M | — | 10.00 | CO | Delaware | 2023-11-01 | ↗ |
| 3 | Ping Lan | 8.46M | 8.54% | — | 8.46M | — | 8.46M | IN | — | 2024-09-06 | ↗ |
| 4 | Ying Luo (“Mr. Luo”) | 8.46M | 8.54% | — | 8.46M | — | 8.46M | IN | — | 2024-09-06 | ↗ |
| 5 | Songjiang Ma (“Mr. Ma”) | 7.46M | 7.62% | — | 7.46M | — | 7.46M | IN | — | 2024-09-06 | ↗ |
| 6 | Yueying Zhu | 7.46M | 7.62% | — | 7.46M | — | 7.46M | IN | — | 2024-09-06 | ↗ |
| 7 | Artal Group S.A. | 6.57M | 12.50% | 6.57M | — | 6.57M | — | OO | — | 2023-02-13 | ↗ |
| 8 | Artal International Management S.A. | 6.57M | 12.50% | 6.57M | — | 6.57M | — | OO | — | 2023-02-13 | ↗ |
| 9 | Artal International S.C.A. | 6.57M | 12.50% | 6.57M | — | 6.57M | — | OO | — | 2023-02-13 | ↗ |
| 10 | Invus Public Equities Advisors, LLC | 6.57M | 12.50% | 6.57M | — | 6.57M | — | OO | — | 2023-02-13 | ↗ |
| 11 | Invus Public Equities, L.P. | 6.57M | 12.50% | 6.57M | — | 6.57M | — | PN | — | 2023-02-13 | ↗ |
| 12 | Mr. Amaury Wittouck | 6.57M | 12.50% | 6.57M | — | 6.57M | — | IN | — | 2023-02-13 | ↗ |
| 13 | Stichting Administratiekantoor Westend | 6.57M | 12.50% | 6.57M | — | 6.57M | — | OO | — | 2023-02-13 | ↗ |
| 14 | Westend S.A. | 6.57M | 12.50% | 6.57M | — | 6.57M | — | OO | — | 2023-02-13 | ↗ |
| 15 | Peter Kolchinsky | 6.38M | 9.90% | — | 6.38M | — | — | HC, IN | United States | 2024-11-06 | ↗ |
| 16 | RA Capital Healthcare Fund, L.P. | 6.38M | 9.90% | — | 6.38M | — | — | PN | Delaware | 2024-11-06 | ↗ |
| 17 | RA Capital Management, L.P. | 6.38M | 9.90% | — | 6.38M | — | — | IA, PN | Delaware | 2024-11-06 | ↗ |
| 18 | Rajeev Shah | 6.38M | 9.90% | — | 6.38M | — | — | HC, IN | United States | 2024-11-06 | ↗ |
| 19 | GNI Hong Kong Limited | 5.37M | 14.20% | — | 5.37M | — | 5.37M | CO | — | 2023-01-05 | ↗ |
| 20 | Adage Capital Management, L.P. | 5.09M | 7.90% | — | 5.09M | — | 10.00 | IA, PN | Delaware | 2024-11-04 | ↗ |
| 21 | Phillip Gross | 5.09M | 7.90% | — | 5.09M | — | 10.00 | HC, IN | United States | 2024-11-04 | ↗ |
| 22 | Robert Atchinson | 5.09M | 7.90% | — | 5.09M | — | 10.00 | HC, IN | United States | 2024-11-04 | ↗ |
| 23 | Arsani William | 5.00M | 11.00% | — | 5.00M | — | 5.00M | HC, IN | United States | 2024-11-27 | ↗ |
| 24 | Logos GP LLC | 5.00M | 11.00% | — | 5.00M | — | 5.00M | OO | Delaware | 2024-11-27 | ↗ |
| 25 | Logos Global Management GP LLC | 5.00M | 11.00% | — | 5.00M | — | 5.00M | HC, OO | Delaware | 2024-11-27 | ↗ |
| 26 | Logos Global Management LP | 5.00M | 11.00% | — | 5.00M | — | 5.00M | IA, PN | Delaware | 2024-11-27 | ↗ |
| 27 | Logos Global Master Fund LP | 5.00M | 11.00% | — | 5.00M | — | 5.00M | PN | Cayman Islands | 2024-11-27 | ↗ |
| 28 | Assenagon S.A., Assenagon Asset Management S.A. | 1.88M | 5.98% | 1.88M | — | 1.88M | — | FI | Reporting | 2022-01-18 | ↗ |
| 29 | Laurence W. Lytton | 1.86M | 11.00% | 1.86M | — | 1.86M | — | IN | — | 2022-03-04 | ↗ |
| 30 | 13-3127734 | 1.77M | 5.64% | 1.35M | — | 1.77M | — | HC | Delaware | 2022-02-11 | ↗ |
| 31 | 26-0385758 | 1.77M | 5.64% | 1.35M | — | 1.77M | — | IA | Delaware | 2022-02-11 | ↗ |
| 32 | OrbiMed Capital LLC | 1.35M | 4.30% | 1.35M | — | 1.35M | — | IA | Delaware | 2022-02-11 | ↗ |
| 33 | (1) BlackRock, Inc. | 886.1K | 1.70% | 865.3K | — | 886.1K | — | HC | Delaware | 2021-07-12 | ↗ |
| 34 | 30-0447847 | 790.2K | 3.60% | 751.7K | — | 790.2K | — | IA | Delaware Limited Partnership | 2021-02-12 | ↗ |
| 35 | Integrated Core Strategies (US) LLC | 683.9K | 3.10% | — | 683.9K | — | 683.9K | OO | — | 2021-02-11 | ↗ |
| 36 | Israel A. Englander | 683.9K | 3.10% | — | 683.9K | — | 683.9K | IN | — | 2021-02-11 | ↗ |
| 37 | Millennium Group Management LLC | 683.9K | 3.10% | — | 683.9K | — | 683.9K | OO | — | 2021-02-11 | ↗ |
| 38 | OrbiMed Advisors LLC | 378.8K | 1.20% | — | 378.8K | — | — | IA | Delaware | 2022-02-11 | ↗ |
| 39 | Acuta Capital Partners, LLC | — | 11.00% | — | — | — | — | IA, OO | Delaware | 2022-02-14 | ↗ |
| 40 | Anupam Dalal | — | 11.00% | — | — | — | — | HC, IN | United States | 2022-02-14 | ↗ |
| 41 | Jon M. Plexico | — | 11.00% | — | — | — | — | HC, IN | U.S.A. | 2022-02-14 | ↗ |
| 42 | Stonepine Capital Management, LLC | — | 11.00% | — | — | — | — | IA, OO | California | 2022-02-14 | ↗ |
| 43 | Stonepine Capital, L.P. | — | 11.00% | — | — | — | — | PN | Delaware | 2022-02-14 | ↗ |
| 44 | Timothy P. Lynch | — | 11.00% | — | — | — | — | HC, IN | U.S.A. | 2022-02-14 | ↗ |
| 45 | Millennium International Management LP | — | 0.00% | — | — | — | — | PN | — | 2021-02-11 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
3
-51 vs prev Q
New positions
2
Closed positions
53
Increased
2
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 372.9K +372.9K (+100.0%) | 4.42B +4.4B (+100.0%) | 0.41% +0.410 pp | 2.59% +2.594 pp | USD11.86 +0.0% | 1 qtrs NEW |
| 2 | FMR LLC | 4.13M +2.7M (+192.2%) | 49.02M +32.2M (+191.5%) | 4.55% +4.513 pp | 0.00% +0.002 pp | USD13.32 -11.0% | 3 qtrs — |
| 3 | BVF INC/IL | 2.75M +1.4M (+98.1%) | 32.60M +16.1M (+97.6%) | 3.03% +2.990 pp | 1.10% +0.429 pp | USD14.02 -15.4% | 3 qtrs — |
| 4 | FAIRMOUNT FUNDS MANAGEMENT LLC | 2.75M +1.4M (+98.0%) | 32.59M +16.1M (+97.5%) | 3.02% +2.989 pp | 2.48% +0.996 pp | USD14.02 -15.4% | 3 qtrs — |
| 5 | VR ADVISER, LLC | 2.13M +745.7K (+53.7%) | 25.30M +8.8M (+53.3%) | 2.35% +2.313 pp | 1.25% +0.321 pp | USD14.64 -19.0% | 3 qtrs — |
| 6 | FCPM III SERVICES B.V. | 1.68M +1.7M (+100.0%) | 19.90M +19.9M (+100.0%) | 1.85% +1.847 pp | 2.61% +2.608 pp | USD11.86 +0.0% | 1 qtrs NEW |
| 7 | VESTAL POINT CAPITAL, LP | 1.50M +1.5M (+100.0%) | 17.79M +17.8M (+100.0%) | 1.65% +1.651 pp | 0.60% +0.605 pp | USD11.86 +0.0% | 1 qtrs NEW |
| 8 | OPALEYE MANAGEMENT INC. | 1.18M +1.2M (+100.0%) | 13.97M +14.0M (+100.0%) | 1.30% +1.297 pp | 1.84% +1.844 pp | USD11.86 +0.0% | 1 qtrs NEW |
| 9 | TANG CAPITAL MANAGEMENT LLC | 872.4K +192.6K (+28.3%) | 10.35M +2.3M (+28.0%) | 0.96% +0.943 pp | 0.51% +0.200 pp | USD12.13 -2.2% | 3 qtrs — |
| 10 | ADAR1 CAPITAL MANAGEMENT, LLC | 606.0K +606.0K (+100.0%) | 7.19M +7.2M (+100.0%) | 0.67% +0.667 pp | 0.53% +0.528 pp | USD11.86 +0.0% | 1 qtrs NEW |
| 11 | LOGOS GLOBAL MANAGEMENT LP | 600.0K +— (+0.0%) | 7.12M -18.0K (-0.3%) | 0.66% +0.645 pp | 0.43% -0.209 pp | USD15.81 -25.0% | 3 qtrs — |
| 12 | VANGUARD GROUP INC | 557.5K -100.4K (-15.3%) | 6.61M -1.2M (-15.5%) | 0.61% +0.597 pp | 0.00% +0.000 pp | USD11.89 -0.3% | 2 qtrs — |
| 13 | PERCEPTIVE ADVISORS LLC | 453.7K +— (+0.0%) | 5.38M -13.6K (-0.3%) | 0.50% +0.488 pp | 0.10% -0.060 pp | USD16.14 -26.5% | 3 qtrs — |
| 14 | BOXER CAPITAL MANAGEMENT, LLC | 453.7K +— (+0.0%) | 5.38M -13.6K (-0.3%) | 0.50% +0.488 pp | 1.18% -0.542 pp | USD16.14 -26.5% | 3 qtrs — |
| 15 | DEEP TRACK CAPITAL, LP | 453.7K +— (+0.0%) | 5.38M -13.6K (-0.3%) | 0.50% +0.488 pp | 0.10% -0.055 pp | USD16.14 -26.5% | 3 qtrs — |
| 16 | RTW INVESTMENTS, LP | 372.9K +372.9K (+100.0%) | 4.42M +4.4M (+100.0%) | 0.41% +0.410 pp | 0.04% +0.044 pp | USD11.86 +0.0% | 1 qtrs NEW |
| 17 | PRICE T ROWE ASSOCIATES INC /MD/ | 338.1K -45.5K (-11.9%) | 4.01M -550.0K (-12.1%) | 0.37% +0.362 pp | 0.00% 0.000 pp | USD11.89 -0.3% | 2 qtrs — |
| 18 | DRIEHAUS CAPITAL MANAGEMENT LLC | 302.5K +— (+0.0%) | 3.59M -9.1K (-0.3%) | 0.33% +0.325 pp | 0.02% -0.001 pp | USD16.14 -26.5% | 3 qtrs — |
| 19 | POINT72 ASSET MANAGEMENT, L.P. | 300.0K +300.0K (+100.0%) | 3.56M +3.6M (+100.0%) | 0.33% +0.330 pp | 0.00% +0.004 pp | USD11.86 +0.0% | 1 qtrs NEW |
| 20 | HEIGHTS CAPITAL MANAGEMENT, INC | 264.0K +264.0K (+100.0%) | 3.13M +3.1M (+100.0%) | 0.29% +0.291 pp | 1.12% +1.123 pp | USD11.86 +0.0% | 1 qtrs NEW |
| 21 | ALYESKA INVESTMENT GROUP, L.P. | 264.0K +264.0K (+100.0%) | 3.11M +3.1M (+100.0%) | 0.29% +0.291 pp | 0.01% +0.009 pp | USD11.86 +0.0% | 1 qtrs NEW |
| 22 | WELLINGTON MANAGEMENT GROUP LLP | 143.4K +125.7K (+710.3%) | 1.63M +1.4M (+673.1%) | 0.16% +0.157 pp | 0.00% +0.000 pp | USD12.39 -4.3% | 3 qtrs — |
| 23 | TWO SIGMA INVESTMENTS, LP | 125.2K +96.9K (+342.2%) | 1.49M +1.1M (+341.1%) | 0.14% +0.137 pp | 0.00% +0.002 pp | USD11.87 -0.1% | 2 qtrs — |
| 24 | BALYASNY ASSET MANAGEMENT L.P. | 111.7K +111.7K (+100.0%) | 1.32M +1.3M (+100.0%) | 0.12% +0.123 pp | 0.00% +0.002 pp | USD11.86 +0.0% | 1 qtrs NEW |
| 25 | BLACKROCK, INC. | 109.2K +115.0 (+0.1%) | 1.30M -1.9K (-0.1%) | 0.12% +0.117 pp | 0.00% +0.000 pp | USD12.13 -2.2% | 3 qtrs — |
| 26 | GEODE CAPITAL MANAGEMENT, LLC | 91.1K +21.9K (+31.7%) | 1.08M +259.0K (+31.5%) | 0.10% +0.099 pp | 0.00% +0.000 pp | USD11.88 -0.2% | 2 qtrs — |
| 27 | STONEPINE CAPITAL MANAGEMENT, LLC | 87.7K +87.7K (+100.0%) | 1.04M +1.0M (+100.0%) | 0.10% +0.097 pp | 0.76% +0.759 pp | USD11.86 +0.0% | 1 qtrs NEW |
| 28 | BLACKSTONE INC. | 75.6K +— (+0.0%) | 896.8K -2.3K (-0.3%) | 0.08% +0.081 pp | 0.00% 0.000 pp | USD16.14 -26.5% | 3 qtrs — |
| 29 | WOODLINE PARTNERS LP | 74.0K +74.0K (+100.0%) | 877.6K +877.6K (+100.0%) | 0.08% +0.082 pp | 0.00% +0.003 pp | USD11.86 +0.0% | 1 qtrs NEW |
| 30 | BURKEHILL GLOBAL MANAGEMENT, LP | 74.0K +74.0K (+100.0%) | 844.3K +844.3K (+100.0%) | 0.08% +0.082 pp | 0.06% +0.056 pp | USD11.86 +0.0% | 1 qtrs NEW |
| 31 | JEFFERIES FINANCIAL GROUP INC. | 64.2K -38.5K (-37.5%) | 761.9K -459.3K (-37.6%) | 0.07% +0.068 pp | 0.00% -0.002 pp | USD13.01 -8.8% | 3 qtrs — |
| 32 | MILLENNIUM MANAGEMENT LLC | 61.9K +61.9K (+100.0%) | 733.9K +733.9K (+100.0%) | 0.07% +0.068 pp | 0.00% +0.000 pp | USD11.86 +0.0% | 1 qtrs NEW |
| 33 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 57.0K +57.0K (+100.0%) | 676.6K +676.6K (+100.0%) | 0.06% +0.063 pp | 0.00% +0.000 pp | USD11.86 +0.0% | 1 qtrs NEW |
| 34 | RENAISSANCE TECHNOLOGIES LLC | 46.7K +19.8K (+73.6%) | 553.9K +234.0K (+73.2%) | 0.05% +0.051 pp | 0.00% +0.000 pp | USD11.88 -0.2% | 2 qtrs — |
| 35 | TWO SIGMA ADVISERS, LP | 32.5K +32.5K (+100.0%) | 385.5K +385.5K (+100.0%) | 0.04% +0.036 pp | 0.00% +0.001 pp | USD11.86 +0.0% | 1 qtrs NEW |
| 36 | MORGAN STANLEY | 27.5K +27.4K (+18,880.0%) | 326.4K +324.7K (+18,832.7%) | 0.03% +0.030 pp | 0.00% +0.000 pp | USD11.88 -0.2% | 3 qtrs — |
| 37 | STATE STREET CORP | 26.2K +7.6K (+40.8%) | 310.9K +89.6K (+40.5%) | 0.03% +0.028 pp | 0.00% +0.000 pp | USD11.88 -0.2% | 2 qtrs — |
| 38 | GOLDMAN SACHS GROUP INC | 25.2K -11.7K (-31.7%) | 299.4K -140.2K (-31.9%) | 0.03% +0.027 pp | 0.00% +0.000 pp | USD11.89 -0.3% | 2 qtrs — |
| 39 | MOORE CAPITAL MANAGEMENT, LP | 25.0K +25.0K (+100.0%) | 296.5K +296.5K (+100.0%) | 0.03% +0.028 pp | 0.00% +0.004 pp | USD11.86 +0.0% | 1 qtrs NEW |
| 40 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 24.9K -20.0 (-0.1%) | 289.0K -7.4K (-2.5%) | 0.03% +0.027 pp | 0.00% +0.000 pp | USD11.89 -0.3% | 2 qtrs — |
| 41 | JPMORGAN CHASE & CO | 23.3K +23.3K (+137,188.2%) | 276.8K +276.6K (+136,930.2%) | 0.01% +0.014 pp | 0.00% +0.000 pp | USD11.86 +0.0% | 2 qtrs — |
| 42 | JANE STREET GROUP, LLC | 23.0K +23.0K (+100.0%) | 272.4K +272.4K (+100.0%) | 0.03% +0.025 pp | 0.00% +0.000 pp | USD11.86 +0.0% | 1 qtrs NEW |
| 43 | MARSHALL WACE, LLP | 21.8K -21.9K (-50.0%) | 258.9K -260.7K (-50.2%) | 0.02% +0.023 pp | 0.00% 0.000 pp | USD11.89 -0.3% | 2 qtrs — |
| 44 | NORTHERN TRUST CORP | 17.2K +413.0 (+2.5%) | 204.3K +4.4K (+2.2%) | 0.02% +0.019 pp | 0.00% +0.000 pp | USD11.89 -0.3% | 2 qtrs — |
| 45 | HRT FINANCIAL LP | 13.1K +13.1K (+100.0%) | 155.0K +155.0K (+100.0%) | 0.01% +0.014 pp | 0.00% +0.001 pp | USD11.86 +0.0% | 1 qtrs NEW |
| 46 | OMERS ADMINISTRATION CORP | 11.6K +11.6K (+100.0%) | 137.6K +137.6K (+100.0%) | 0.01% +0.013 pp | 0.00% +0.001 pp | USD11.86 +0.0% | 1 qtrs NEW |
| 47 | UBS GROUP AG | 7.1K -5.5K (-43.7%) | 84.5K -66.0K (-43.9%) | 0.01% +0.008 pp | 0.00% +0.000 pp | USD11.96 -0.8% | 3 qtrs — |
| 48 | BANK OF AMERICA CORP /DE/ | 5.6K +1.7K (+44.3%) | 66.1K +20.2K (+43.9%) | 0.01% +0.006 pp | 0.00% +0.000 pp | USD14.83 -20.0% | 3 qtrs — |
| 49 | BNP PARIBAS ARBITRAGE, SNC | 3.6K +3.6K (+89,525.0%) | 42.5K +42.5K (+88,479.2%) | 0.00% +0.004 pp | 0.00% +0.000 pp | USD11.86 +0.0% | 3 qtrs — |
| 50 | CITIGROUP INC | 623.00 -175.0 (-21.9%) | 7.4K -2.1K (-22.1%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD11.89 -0.3% | 2 qtrs — |
| 51 | TOWER RESEARCH CAPITAL LLC (TRC) | 409.00 +209.0 (+104.5%) | 4.9K +2.5K (+104.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD11.87 -0.1% | 2 qtrs — |
| 52 | SBI SECURITIES CO., LTD. | 68.00 +— (+0.0%) | 806.00 -3.0 (-0.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD16.13 -26.5% | 3 qtrs — |
| 53 | ADVISOR GROUP HOLDINGS, INC. | 26.00 +— (+0.0%) | 308.00 -66.0 (-17.6%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD11.88 -0.2% | 2 qtrs — |
| 54 | GROUP ONE TRADING, L.P. | 4.00 -78.0 (-95.1%) | 47.00 -928.0 (-95.2%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD16.00 -25.9% | 3 qtrs — |
| 55 | FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | — -273.0K (-100.0%) | — -3.2M (-100.0%) | 0.00% -0.007 pp | 0.00% -0.097 pp | USD— | 3 qtrs SOLD |
| 56 | CITADEL ADVISORS LLC | — -25.6K (-100.0%) | — -304.3K (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 57 | COMMODORE CAPITAL LP | — -450.8K (-100.0%) | — -5.4M (-100.0%) | 0.00% -0.012 pp | 0.00% -0.262 pp | USD— | 3 qtrs SOLD |
| 58 | AFFINITY ASSET ADVISORS, LLC | — -18.0K (-100.0%) | — -214.0K (-100.0%) | 0.00% -0.001 pp | 0.00% -0.019 pp | USD— | 3 qtrs SOLD |
| 59 | SOLEUS CAPITAL MANAGEMENT, L.P. | — -200.0K (-100.0%) | — -2.4M (-100.0%) | 0.00% -0.005 pp | 0.00% -0.120 pp | USD— | 3 qtrs SOLD |
| 60 | ADAGE CAPITAL PARTNERS GP, L.L.C. | — -200.0K (-100.0%) | — -2.4M (-100.0%) | 0.00% -0.005 pp | 0.00% -0.004 pp | USD— | 3 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 37 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Virtus Biotech Clinical Trials ETF BBC | 0.60% | 342.8K | 0.65% |
| 2 | iShares Micro-Cap ETF IWC | 0.08% | 1.26M | 0.60% |
| 3 | iShares Russell 2000 Growth ETF IWO | 0.02% | 3.53M | 0.24% |
| 4 | Avantis U.S. Small Cap Equity ETF AVSC | 0.01% | 395.8K | 0.25% |
| 5 | Xtrackers Russell 2000 UCITS ETF 1C XRSU.L | 0.01% | 352.8K | 0.30% |
| 6 | State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc) R2US.L | 0.01% | 667.7K | 0.30% |
| 7 | Invesco Russell 2000 UCITS ETF RTYS.L | 0.01% | 37.9K | 0.25% |
| 8 | Global X - Russell 2000 ETF RSSL | 0.01% | 174.4K | 0.08% |
| 9 | iShares Russell 2000 BuyWrite ETF IWMW | 0.01% | 6.4K | 0.39% |
| 10 | iShares Russell 2000 ETF IWM | 0.01% | 9.29M | 0.19% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
28
Sells
0
Shares acquired
2.82M
Shares disposed
—
Cash buys
2.00
Cash sales
—
Net activity
+2,823,258
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-15 | Scalzo Richard William | Officer | A-Award | A | Ordinary Shares | 14,422 | 0.00 | — | 14,422 | D | ↗ |
| 2025-12-15 | Pinkas Jan | Officer | A-Award | A | Stock Option (Right to Buy) | 70,025 | 13.21 | 925.0K | 70,025 | D | ↗ |
| 2025-12-15 | McNeill Jonathan | Officer | A-Award | A | Ordinary Shares | 6,000 | 0.00 | — | 159,707 | D | ↗ |
| 2025-12-15 | Lynch Ryan | Officer | A-Award | A | Ordinary Shares | 8,378 | 0.00 | — | 8,378 | D | ↗ |
| 2025-12-15 | Im Ellie Eunkyung | Officer | A-Award | A | Ordinary Shares | 16,298 | 0.00 | — | 16,298 | D | ↗ |
| 2025-12-15 | Doughty Christopher Grant | Officer | A-Award | A | Ordinary Shares | 14,714 | 0.00 | — | 54,194 | D | ↗ |
| 2025-12-15 | Brumm Joshua T | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 180,467 | 13.21 | 2.38M | 180,467 | D | ↗ |
| 2025-12-15 | Bispham Barbara Harlin | Officer | A-Award | A | Ordinary Shares | 6,000 | 0.00 | — | 18,422 | D | ↗ |
| 2025-12-08 | McNeill Jonathan | Officer | A-Award | A | Stock Option (Right to Buy) | 172,836 | 13.17 | 2.28M | 172,836 | D | ↗ |
| 2025-12-08 | Brumm Joshua T | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 345,672 | 13.17 | 4.55M | 345,672 | D | ↗ |
| 2025-12-04 | Fairmount Funds Management LLC | Director / 10% Owner | P-Purchase | A | Ordinary Shares | 1,360,000 | 13.41 | 18.24M | 2,747,866 | I | ↗ |
| 2025-07-16 | Pinkas Jan | Officer | A-Award | A | Stock Option (Right to Buy) | 142,474 | 13.14 | 1.87M | 142,474 | D | ↗ |
| 2025-07-07 | Pinkas Jan | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-06-23 | Violin Jonathan | Director | A-Award | A | Stock Option (Right to Buy) | 9,023 | 15.30 | 138.1K | 9,023 | D | ↗ |
| 2025-06-23 | Moran Susan | Director | A-Award | A | Stock Option (Right to Buy) | 9,023 | 15.30 | 138.1K | 9,023 | D | ↗ |
| 2025-06-23 | Lubner David Charles | Director | A-Award | A | Stock Option (Right to Buy) | 9,023 | 15.30 | 138.1K | 9,023 | D | ↗ |
| 2025-06-23 | Fairmount Funds Management LLC | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 9,023 | 15.30 | 138.1K | 9,023 | I | ↗ |
| 2025-06-23 | Balcom Alexandra | Director | A-Award | A | Stock Option (Right to Buy) | 9,023 | 15.30 | 138.1K | 9,023 | D | ↗ |
| 2024-08-08 | Invus Public Equities, L.P. | 10% Owner | S-Sale | D | Common Stock | 260,873 | 0.19 | 50.0K | 6,317,565 | — | ↗ |
| 2024-08-07 | Invus Public Equities, L.P. | 10% Owner | S-Sale | D | Common Stock | 61,488 | 0.18 | 11.2K | 6,578,438 | — | ↗ |
| 2024-08-06 | Invus Public Equities, L.P. | 10% Owner | S-Sale | D | Common Stock | 55,732 | 0.18 | 10.2K | 6,639,926 | — | ↗ |
| 2024-08-05 | Invus Public Equities, L.P. | 10% Owner | S-Sale | D | Common Stock | 164,523 | 0.19 | 31.0K | 6,695,658 | — | ↗ |
| 2024-08-02 | Invus Public Equities, L.P. | 10% Owner | S-Sale | D | Common Stock | 286,200 | 0.20 | 57.4K | 6,860,181 | — | ↗ |
| 2024-08-01 | Invus Public Equities, L.P. | 10% Owner | S-Sale | D | Common Stock | 63,564 | 0.22 | 13.7K | 7,146,381 | — | ↗ |
| 2024-07-30 | Invus Public Equities, L.P. | 10% Owner | S-Sale | D | Common Stock | 756,835 | 0.22 | 167.2K | 7,209,945 | — | ↗ |
| 2024-07-29 | Invus Public Equities, L.P. | 10% Owner | S-Sale | D | Common Stock | 363,949 | 0.24 | 85.6K | 7,966,780 | — | ↗ |
| 2024-07-26 | Invus Public Equities, L.P. | 10% Owner | S-Sale | D | Common Stock | 258,335 | 0.24 | 62.4K | 8,330,729 | — | ↗ |
| 2024-07-25 | Siren, L.L.C. | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 8,589,064 | — | ↗ |
| 2024-06-21 | Rock Edwin | Officer | P-Purchase | A | Common Stock | 115,000 | 0.27 | 30.7K | 680,403 | — | ↗ |
| 2024-06-20 | Rock Edwin | Officer | P-Purchase | A | Common Stock | 190,000 | 0.25 | 48.1K | 565,403 | — | ↗ |
| 2024-06-18 | Hahn Brian M. | Officer | P-Purchase | A | Common Stock | 17,500 | 0.25 | 4.3K | 70,643 | — | ↗ |
| 2024-05-01 | PEARSON TIMOTHY R | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 1.62 | 64.8K | 40,000 | — | ↗ |
| 2024-05-01 | Koenig Scott | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 1.62 | 64.8K | 40,000 | — | ↗ |
| 2024-05-01 | King Rachel K. | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 1.62 | 64.8K | 40,000 | — | ↗ |
| 2024-05-01 | Jackson Scott Thomas | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 1.62 | 64.8K | 40,000 | — | ↗ |
| 2024-05-01 | JUNIUS DANIEL M | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 1.62 | 64.8K | 40,000 | — | ↗ |
| 2024-05-01 | Goldberg Mark Alan | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 1.62 | 64.8K | 40,000 | — | ↗ |
| 2024-05-01 | Andrews Patricia S | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 1.62 | 64.8K | 40,000 | — | ↗ |
| 2024-03-29 | King Rachel K. | Director | A-Award | A | Common Stock | 3,334 | 3.00 | 10.0K | 515,194 | — | ↗ |
| 2024-03-29 | JUNIUS DANIEL M | Director | A-Award | A | Common Stock | 5,209 | 3.00 | 15.6K | 98,459 | — | ↗ |
| 2024-03-29 | Goldberg Mark Alan | Director | A-Award | A | Common Stock | 4,584 | 3.00 | 13.8K | 24,828 | — | ↗ |
| 2024-01-12 | Semerjian Harout | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 695,000 | 3.11 | 2.16M | 695,000 | — | ↗ |
| 2024-01-12 | Rock Edwin | Officer | A-Award | A | Employee Stock Option (right to buy) | 250,000 | 3.11 | 777.5K | 250,000 | — | ↗ |
| 2024-01-12 | Rath Chinmaya | Officer | A-Award | A | Employee Stock Option (right to buy) | 250,000 | 3.11 | 777.5K | 250,000 | — | ↗ |
| 2024-01-12 | Johnson Bruce S | Officer | A-Award | A | Employee Stock Option (right to buy) | 250,000 | 3.11 | 777.5K | 250,000 | — | ↗ |
| 2024-01-12 | Hahn Brian M. | Officer | A-Award | A | Employee Stock Option (right to buy) | 250,000 | 3.11 | 777.5K | 250,000 | — | ↗ |
| 2023-12-29 | King Rachel K. | Director | A-Award | A | Common stock | 4,238 | 2.36 | 10.0K | 511,860 | — | ↗ |
| 2023-12-29 | Goldberg Mark Alan | Director | A-Award | A | Common stock | 5,827 | 2.36 | 13.8K | 20,244 | — | ↗ |
| 2023-12-29 | Andrews Patricia S | Director | A-Award | A | Common stock | 5,191 | 2.36 | 12.3K | 58,608 | — | ↗ |
| 2023-09-30 | King Rachel K. | Director | A-Award | A | Common stock | 6,667 | 1.50 | 10.0K | 507,622 | — | ↗ |
| 2023-09-30 | Goldberg Mark Alan | Director | A-Award | A | Common stock | 9,167 | 1.50 | 13.8K | 14,417 | — | ↗ |
| 2023-09-30 | Andrews Patricia S | Director | A-Award | A | Common stock | 8,167 | 1.50 | 12.3K | 53,417 | — | ↗ |
| 2023-09-22 | Rock Edwin | Officer | P-Purchase | A | Common Stock | 30,403 | 1.38 | 42.0K | 375,403 | — | ↗ |
| 2023-09-21 | Rock Edwin | Officer | P-Purchase | A | Common Stock | 35,000 | 1.38 | 48.3K | 345,000 | — | ↗ |
| 2023-06-01 | Koenig Scott | Director | M-Exempt | A | Common Stock | 21,000 | 0.60 | 12.6K | 36,750 | — | ↗ |
| 2023-05-19 | PEARSON TIMOTHY R | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 1.98 | 69.3K | 35,000 | — | ↗ |
| 2023-05-19 | Koenig Scott | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 1.98 | 69.3K | 35,000 | — | ↗ |
| 2023-05-19 | King Rachel K. | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 1.98 | 69.3K | 35,000 | — | ↗ |
| 2023-05-19 | Jackson Scott Thomas | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 1.98 | 69.3K | 35,000 | — | ↗ |
| 2023-05-19 | JUNIUS DANIEL M | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 1.98 | 69.3K | 35,000 | — | ↗ |
| 2023-05-19 | Goldberg Mark Alan | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 1.98 | 69.3K | 35,000 | — | ↗ |
| 2023-05-19 | Andrews Patricia S | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 1.98 | 69.3K | 35,000 | — | ↗ |
| 2023-05-17 | Hahn Brian M. | Officer | S-Sale | D | Common Stock | 3,700 | 1.95 | 7.2K | 53,143 | — | ↗ |
| 2023-05-10 | JUNIUS DANIEL M | Director | P-Purchase | A | Common Stock | 30,000 | 1.56 | 46.8K | 93,250 | — | ↗ |
| 2023-05-08 | Johnson Bruce S | Officer | P-Purchase | A | Common Stock | 13,500 | 1.57 | 21.2K | 138,980 | — | ↗ |
| 2023-03-23 | Rath Chinmaya | Officer | — | D | Common Stock | 0 | 0.00 | — | 161,178 | — | ↗ |
| 2023-03-23 | Johnson Bruce S | Officer | — | D | Common Stock | 0 | 0.00 | — | 125,480 | — | ↗ |
| 2023-02-24 | Invus Public Equities, L.P. | 10% Owner | P-Purchase | A | Common Stock | 100,000 | 1.70 | 170.0K | 8,589,064 | — | ↗ |
| 2023-02-23 | Invus Public Equities, L.P. | 10% Owner | P-Purchase | A | Common Stock | 200,000 | 1.75 | 350.8K | 8,489,064 | — | ↗ |
| 2023-02-22 | Invus Public Equities, L.P. | 10% Owner | P-Purchase | A | Common Stock | 150,000 | 1.79 | 269.0K | 8,289,064 | — | ↗ |
| 2023-02-21 | Invus Public Equities, L.P. | 10% Owner | P-Purchase | A | Common Stock | 50,000 | 1.85 | 92.5K | 8,139,064 | — | ↗ |
| 2023-02-17 | Invus Public Equities, L.P. | 10% Owner | P-Purchase | A | Common Stock | 200,000 | 1.71 | 341.0K | 8,089,064 | — | ↗ |
| 2023-02-16 | Invus Public Equities, L.P. | 10% Owner | P-Purchase | A | Common Stock | 315,266 | 1.68 | 531.1K | 7,889,064 | — | ↗ |
| 2023-02-15 | Invus Public Equities, L.P. | 10% Owner | P-Purchase | A | Common Stock | 1,000,000 | 2.16 | 2.16M | 7,573,798 | — | ↗ |
| 2023-02-09 | Invus Public Equities, L.P. | 10% Owner | P-Purchase | A | Common Stock | 11,451 | 3.24 | 37.1K | 6,573,798 | — | ↗ |
| 2023-01-27 | Koenig Scott | Director | M-Exempt | A | Common Stock | 10,500 | 2.55 | 26.8K | 15,750 | — | ↗ |
| 2023-01-26 | SANDELL SCOTT D | Director | S-Sale | D | Common Stock | 1,648,908 | 3.12 | 5.14M | 2,730,334 | — | ↗ |
| 2023-01-25 | SANDELL SCOTT D | Director | S-Sale | D | Common Stock | 358,371 | 3.26 | 1.17M | 4,379,242 | — | ↗ |
| 2023-01-19 | Semerjian Harout | Officer | A-Award | A | Employee Stock Option (right to buy) | 651,200 | 0.00 | — | 651,200 | — | ↗ |
| 2023-01-19 | Rock Edwin | Officer | A-Award | A | Employee Stock Option (right to buy) | 244,800 | 0.00 | — | 244,800 | — | ↗ |
| 2023-01-19 | Hahn Brian M. | Officer | A-Award | A | Employee Stock Option (right to buy) | 246,300 | 0.00 | — | 246,300 | — | ↗ |
| 2023-01-05 | SANDELL SCOTT D | Director | S-Sale | D | Common Stock | 39,223 | 2.76 | 108.2K | 4,737,613 | — | ↗ |
| 2023-01-04 | SANDELL SCOTT D | Director | S-Sale | D | Common Stock | 56,054 | 2.91 | 163.1K | 4,776,836 | — | ↗ |
| 2023-01-03 | SANDELL SCOTT D | Director | S-Sale | D | Common Stock | 96,084 | 2.99 | 287.3K | 4,832,890 | — | ↗ |
| 2022-12-31 | King Rachel K. | Director | — | I | Common Stock | 0 | 0.00 | — | 45,741 | — | ↗ |
| 2022-12-30 | SANDELL SCOTT D | Director | S-Sale | D | Common Stock | 66,690 | 3.02 | 201.4K | 4,928,974 | — | ↗ |
| 2022-12-22 | Rock Edwin | Officer | P-Purchase | A | Common Stock | 110,000 | 2.25 | 247.5K | 310,000 | — | ↗ |
| 2022-11-17 | JUNIUS DANIEL M | Director | P-Purchase | A | Common Stock | 20,000 | 1.87 | 37.4K | 63,250 | — | ↗ |
| 2022-11-15 | Rock Edwin | Officer | P-Purchase | A | Common Stock | 100,000 | 1.66 | 166.0K | 200,000 | — | ↗ |
| 2022-11-14 | Rock Edwin | Officer | P-Purchase | A | Common Stock | 100,000 | 1.43 | 143.0K | 100,000 | — | ↗ |
| 2022-11-11 | Semerjian Harout | Officer | P-Purchase | A | Common Stock | 25,000 | 1.29 | 32.3K | 25,000 | — | ↗ |
| 2022-11-11 | PEARSON TIMOTHY R | Director | P-Purchase | A | Common Stock | 19,400 | 1.29 | 25.0K | 24,650 | — | ↗ |
| 2022-11-11 | Magnani John L. | Officer | P-Purchase | A | Common Stock | 45,045 | 1.17 | 52.7K | 366,078 | — | ↗ |
| 2022-11-11 | Hahn Brian M. | Officer | P-Purchase | A | Common Stock | 20,000 | 1.06 | 21.2K | 56,843 | — | ↗ |
| 2022-11-11 | Girard Armand | Officer | P-Purchase | A | Common Stock | 6,500 | 1.05 | 6.8K | 29,161 | — | ↗ |
| 2022-09-02 | Rock Edwin | Officer | A-Award | A | Employee stock option (right to buy) | 200,000 | 0.00 | — | 200,000 | — | ↗ |
| 2022-05-18 | PEARSON TIMOTHY R | Director | A-Award | A | Stock Option (right to buy) | 21,000 | 0.00 | — | 21,000 | — | ↗ |
| 2022-05-18 | Koenig Scott | Director | A-Award | A | Stock Option (right to buy) | 21,000 | 0.60 | 12.6K | 21,000 | — | ↗ |
| 2022-05-18 | King Rachel K. | Director | A-Award | A | Stock Option (right to buy) | 21,000 | 0.60 | 12.6K | 21,000 | — | ↗ |
| 2022-05-18 | Jackson Scott Thomas | Director | A-Award | A | Stock Option (right to buy) | 21,000 | 0.00 | — | 21,000 | — | ↗ |
| 2022-05-18 | JUNIUS DANIEL M | Director | A-Award | A | Stock Option (right to buy) | 21,000 | 0.60 | 12.6K | 21,000 | — | ↗ |
| 2022-05-18 | Goldberg Mark Alan | Director | A-Award | A | Stock Option (right to buy) | 21,000 | 0.60 | 12.6K | 21,000 | — | ↗ |
| 2022-05-18 | Andrews Patricia S | Director | A-Award | A | Stock Option (right to buy) | 21,000 | 0.00 | — | 21,000 | — | ↗ |
| 2022-03-09 | Magnani John L. | Officer | S-Sale | D | Common Stock | 3,227 | 1.09 | 3.5K | 321,033 | — | ↗ |
| 2022-03-09 | Hahn Brian M. | Officer | S-Sale | D | Common Stock | 2,917 | 1.09 | 3.2K | 36,843 | — | ↗ |
| 2022-03-09 | Girard Armand | Officer | S-Sale | D | Common Stock | 2,339 | 1.09 | 2.5K | 22,661 | — | ↗ |
| 2022-01-21 | Semerjian Harout | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 423,500 | 1.11 | 470.1K | 423,500 | — | ↗ |
| 2022-01-21 | Magnani John L. | Officer | A-Award | A | Employee Stock Option (right to buy) | 25,000 | 1.11 | 27.8K | 25,000 | — | ↗ |
| 2022-01-21 | Hahn Brian M. | Officer | A-Award | A | Employee Stock Option (right to buy) | 47,700 | 1.11 | 52.9K | 47,700 | — | ↗ |
| 2022-01-21 | Girard Armand | Officer | A-Award | A | Employee Stock Option (right to buy) | 47,700 | 1.11 | 52.9K | 47,700 | — | ↗ |
| 2021-11-16 | Andrews Patricia S | Director | P-Purchase | A | Common Stock | 40,000 | 2.05 | 82.0K | 45,250 | — | ↗ |
| 2021-08-06 | Semerjian Harout | Director / Officer | — | D | No securities beneficially owned | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-05-18 | PEARSON TIMOTHY R | Director | A-Award | A | Common Stock | 5,250 | 0.00 | — | 5,250 | — | ↗ |
| 2021-05-18 | Koenig Scott | Director | A-Award | A | Stock Option (right to buy) | 10,500 | 2.55 | 26.8K | 10,500 | — | ↗ |
| 2021-05-18 | Jackson Scott Thomas | Director | A-Award | A | Stock Option (right to buy) | 10,500 | 2.55 | 26.8K | 10,500 | — | ↗ |
| 2021-05-18 | JUNIUS DANIEL M | Director | A-Award | A | Stock Option (right to buy) | 10,500 | 2.55 | 26.8K | 10,500 | — | ↗ |
| 2021-05-18 | Goldberg Mark Alan | Director | A-Award | A | Common Stock | 5,250 | 0.00 | — | 5,250 | — | ↗ |
| 2021-05-18 | Andrews Patricia S | Director | A-Award | A | Common Stock | 5,250 | 0.00 | — | 5,250 | — | ↗ |
| 2021-03-01 | Feldman Eric Jay | Officer | — | D | Common Stock | 0 | 0.00 | — | 50,498 | — | ↗ |
| 2021-01-20 | Thackray Helen M. | Officer | A-Award | A | Employee Stock Option (right to buy) | 69,000 | 3.81 | 262.9K | 69,000 | — | ↗ |
| 2021-01-20 | Magnani John L. | Officer | A-Award | A | Employee Stock Option (right to buy) | 69,000 | 3.81 | 262.9K | 69,000 | — | ↗ |
| 2021-01-20 | King Rachel K. | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 192,500 | 3.81 | 733.4K | 192,500 | — | ↗ |
| 2021-01-20 | Hahn Brian M. | Officer | A-Award | A | Common Stock | 34,500 | 0.00 | — | 39,760 | — | ↗ |
| 2021-01-20 | Girard Armand | Officer | A-Award | A | Common Stock | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2020-12-28 | King Rachel K. | Director / Officer | M-Exempt | A | Common Stock | 130,821 | 1.12 | 146.5K | 440,240 | — | ↗ |
| 2020-12-16 | Hahn Brian M. | Officer | M-Exempt | A | Common Stock | 5,260 | 1.12 | 5.9K | 5,260 | — | ↗ |
| 2020-11-04 | BVF PARTNERS L P/IL | 10% Owner | P-Purchase | A | Common Stock, $0.001 par value | 674,492 | 2.60 | 1.75M | 4,980,812 | — | ↗ |
| 2020-10-30 | BVF PARTNERS L P/IL | 10% Owner | P-Purchase | A | Common Stock, $0.001 par value | 15,472 | 2.75 | 42.5K | 544,363 | — | ↗ |
| 2020-05-22 | PEARSON TIMOTHY R | Director | A-Award | A | Stock Option (right to buy) | 21,000 | 3.00 | 63.0K | 21,000 | — | ↗ |
| 2020-05-22 | Koenig Scott | Director | A-Award | A | Stock Option (right to buy) | 21,000 | 3.00 | 63.0K | 21,000 | — | ↗ |
| 2020-05-22 | Jackson Scott Thomas | Director | A-Award | A | Stock Option (right to buy) | 21,000 | 3.00 | 63.0K | 21,000 | — | ↗ |
| 2020-05-22 | JUNIUS DANIEL M | Director | A-Award | A | Stock Option (right to buy) | 21,000 | 3.00 | 63.0K | 21,000 | — | ↗ |
| 2020-05-22 | Goldberg Mark Alan | Director | A-Award | A | Stock Option (right to buy) | 21,000 | 3.00 | 63.0K | 21,000 | — | ↗ |
| 2020-05-22 | Andrews Patricia S | Director | A-Award | A | Stock Option (right to buy) | 21,000 | 3.00 | 63.0K | 21,000 | — | ↗ |
| 2020-03-09 | JUNIUS DANIEL M | Director | P-Purchase | A | Common Stock | 20,000 | 3.40 | 68.0K | 38,000 | — | ↗ |
| 2020-01-22 | Thackray Helen M. | Officer | A-Award | A | Employee Stock Option (right to buy) | 120,000 | 4.72 | 566.4K | 120,000 | — | ↗ |
| 2020-01-22 | Magnani John L. | Officer | A-Award | A | Employee Stock Option (right to buy) | 120,000 | 4.72 | 566.4K | 120,000 | — | ↗ |
| 2020-01-22 | King Rachel K. | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 349,000 | 4.72 | 1.65M | 349,000 | — | ↗ |
| 2020-01-22 | Hahn Brian M. | Officer | A-Award | A | Employee Stock Option (right to buy) | 120,000 | 4.72 | 566.4K | 120,000 | — | ↗ |
| 2020-01-22 | Girard Armand | Officer | A-Award | A | Employee Stock Option (right to buy) | 100,000 | 4.72 | 472.0K | 100,000 | — | ↗ |
| 2020-01-06 | Magnani John L. | Officer | M-Exempt | A | Common Stock | 106,983 | 1.12 | 119.8K | 289,760 | — | ↗ |
| 2019-12-20 | Magnani John L. | Officer | M-Exempt | A | Common Stock | 106,984 | 1.12 | 119.8K | 182,777 | — | ↗ |
| 2019-09-05 | BVF PARTNERS L P/IL | 10% Owner | P-Purchase | A | Common Stock, $0.001 par value | 853,956 | 3.18 | 2.72M | 3,639,935 | — | ↗ |
| 2019-08-15 | BVF PARTNERS L P/IL | 10% Owner | — | D | Common Stock, $0.001 par value | 0 | 0.00 | — | 2,785,979 | — | ↗ |
| 2019-08-13 | JUNIUS DANIEL M | Director | P-Purchase | A | Common Stock | 10,000 | 3.18 | 31.8K | 18,000 | — | ↗ |
| 2019-08-06 | King Rachel K. | Director / Officer | M-Exempt | A | Common Stock | 166,759 | 1.12 | 186.8K | 307,144 | — | ↗ |
| 2019-05-17 | PEARSON TIMOTHY R | Director | A-Award | A | Common Stock | 21,000 | 12.39 | 260.2K | 21,000 | — | ↗ |
| 2019-05-17 | Koenig Scott | Director | A-Award | A | Stock Option (right to buy) | 21,000 | 12.39 | 260.2K | 21,000 | — | ↗ |
| 2019-05-17 | Jackson Scott Thomas | Director | A-Award | A | Stock Option (right to buy) | 21,000 | 12.39 | 260.2K | 21,000 | — | ↗ |
| 2019-05-17 | JUNIUS DANIEL M | Director | A-Award | A | Stock Option (right to buy) | 21,000 | 12.39 | 260.2K | 21,000 | — | ↗ |
| 2019-05-17 | Goldberg Mark Alan | Director | A-Award | A | Stock Option (right to buy) | 21,000 | 12.39 | 260.2K | 21,000 | — | ↗ |
| 2019-05-17 | Andrews Patricia S | Director | A-Award | A | Stock Option (right to buy) | 21,000 | 12.39 | 260.2K | 21,000 | — | ↗ |
| 2019-03-01 | Girard Armand | Officer | — | D | Employee Stock Option (right to buy) | 5,516 | 7.15 | 39.4K | 0 | — | ↗ |
| 2019-01-17 | Thackray Helen M. | Officer | A-Award | A | Employee Stock Option (right to buy) | 100,000 | 10.59 | 1.06M | 100,000 | — | ↗ |
| 2019-01-17 | Magnani John L. | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 100,000 | 10.59 | 1.06M | 100,000 | — | ↗ |
| 2019-01-17 | King Rachel K. | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 265,000 | 10.59 | 2.81M | 265,000 | — | ↗ |
| 2019-01-17 | Hahn Brian M. | Officer | A-Award | A | Employee Stock Option (right to buy) | 90,000 | 10.59 | 953.1K | 90,000 | — | ↗ |
| 2018-11-27 | Jackson Scott Thomas | Director | — | D | No securities beneficially owned | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-10-18 | Magnani John L. | Director / Officer | S-Sale | D | Common Stock | 3,527 | 14.02 | 49.4K | 75,793 | — | ↗ |
| 2018-10-17 | Magnani John L. | Director / Officer | S-Sale | D | Common Stock | 7,273 | 14.00 | 101.8K | 79,320 | — | ↗ |
| 2018-10-16 | Magnani John L. | Director / Officer | S-Sale | D | Common Stock | 14,200 | 14.01 | 198.9K | 86,593 | — | ↗ |
| 2018-06-11 | Hahn Brian M. | Officer | M-Exempt | A | Common Stock | 5,260 | 1.12 | 5.9K | 19,345 | — | ↗ |
| 2018-05-23 | Magnani John L. | Director / Officer | M-Exempt | A | Common Stock | 1,491 | 0.33 | 492.03 | 100,793 | — | ↗ |
| 2018-05-18 | PEARSON TIMOTHY R | Director | A-Award | A | Stock Option (right to buy) | 11,000 | 18.41 | 202.5K | 11,000 | — | ↗ |
| 2018-05-18 | Koenig Scott | Director | A-Award | A | Stock Option (right to buy) | 11,000 | 18.41 | 202.5K | 11,000 | — | ↗ |
| 2018-05-18 | JUNIUS DANIEL M | Director | A-Award | A | Stock Option (right to buy) | 11,000 | 18.41 | 202.5K | 11,000 | — | ↗ |
| 2018-05-18 | Goldberg Mark Alan | Director | A-Award | A | Stock Option (right to buy) | 11,000 | 18.41 | 202.5K | 11,000 | — | ↗ |
| 2018-05-18 | BARRETT M JAMES | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 11,000 | 18.41 | 202.5K | 11,000 | — | ↗ |
| 2018-05-18 | Andrews Patricia S | Director | A-Award | A | Stock Option (right to buy) | 11,000 | 18.41 | 202.5K | 11,000 | — | ↗ |
| 2018-05-10 | SANDELL SCOTT D | 10% Owner | X-InTheMoney | D | Warrant to Purchase Common Stock (right to buy) | 298,406 | 0.33 | 98.5K | 0 | — | ↗ |
| 2018-05-10 | NEW ENTERPRISE ASSOCIATES 10 L P | 10% Owner | X-InTheMoney | A | Common Stock | 216,046 | 0.33 | 71.3K | 4,706,797 | — | ↗ |
| 2018-05-10 | BARRIS PETER J | 10% Owner | X-InTheMoney | D | Warrant to Purchase Common Stock (right to buy) | 298,406 | 0.33 | 98.5K | 0 | — | ↗ |
| 2018-05-10 | BARRETT M JAMES | Director / 10% Owner | X-InTheMoney | D | Warrant to Purchase Common Stock (right to buy) | 298,406 | 0.33 | 98.5K | 0 | — | ↗ |
| 2018-01-10 | Thackray Helen M. | Officer | A-Award | A | Employee Stock Option (right to buy) | 75,000 | 20.03 | 1.50M | 75,000 | — | ↗ |
| 2018-01-10 | Magnani John L. | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 75,000 | 20.03 | 1.50M | 75,000 | — | ↗ |
| 2018-01-10 | King Rachel K. | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 175,000 | 20.03 | 3.51M | 175,000 | — | ↗ |
| 2018-01-10 | Hahn Brian M. | Officer | A-Award | A | Employee Stock Option (right to buy) | 65,000 | 20.03 | 1.30M | 65,000 | — | ↗ |
| 2017-12-31 | King Rachel K. | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 140,385 | — | ↗ |
| 2017-12-08 | Thackray Helen M. | Officer | S-Sale | D | Common Stock | 2,000 | 15.01 | 30.0K | 148,615 | — | ↗ |
| 2017-09-18 | Thackray Helen M. | Officer | S-Sale | D | Common Stock | 2,000 | 13.00 | 26.0K | 150,615 | — | ↗ |
| 2017-06-15 | JUNIUS DANIEL M | Director | A-Award | A | Common Stock | 3,000 | 11.27 | 33.8K | 8,000 | — | ↗ |
| 2017-06-09 | Andrews Patricia S | Director | A-Award | A | Stock Option (right to buy) | 22,000 | 11.63 | 255.9K | 22,000 | — | ↗ |
| 2017-05-25 | Thackray Helen M. | Officer | S-Sale | D | Common Stock | 2,000 | 15.57 | 31.1K | 152,615 | — | ↗ |
| 2017-05-25 | PEARSON TIMOTHY R | Director | A-Award | A | Stock Option (right to buy) | 11,000 | 13.89 | 152.8K | 11,000 | — | ↗ |
| 2017-05-25 | Koenig Scott | Director | A-Award | A | Stock Option (right to buy) | 11,000 | 13.89 | 152.8K | 11,000 | — | ↗ |
| 2017-05-25 | JUNIUS DANIEL M | Director | A-Award | A | Stock Option (right to buy) | 11,000 | 13.89 | 152.8K | 11,000 | — | ↗ |
| 2017-05-25 | Goldberg Mark Alan | Director | A-Award | A | Stock Option (right to buy) | 11,000 | 13.89 | 152.8K | 11,000 | — | ↗ |
| 2017-05-25 | BARRETT M JAMES | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 11,000 | 13.89 | 152.8K | 11,000 | — | ↗ |
| 2017-05-19 | Thackray Helen M. | Officer | S-Sale | D | Common Stock | 2,000 | 12.14 | 24.3K | 154,615 | — | ↗ |
| 2017-05-10 | Magnani John L. | Director / Officer | M-Exempt | D | Employee Stock Option (right to buy) | 8,928 | 1.12 | 10.0K | 213,967 | — | ↗ |
| 2017-05-01 | BVF PARTNERS L P/IL | 10% Owner | — | D | Common Stock, $0.001 par value per share | 0 | 0.00 | — | 1,644,624 | — | ↗ |
| 2017-03-09 | Koenig Scott | Director | A-Award | A | Stock Option (right to buy) | 22,000 | 6.59 | 145.0K | 22,000 | — | ↗ |
| 2017-01-04 | Thackray Helen M. | Officer | A-Award | A | Employee Stock Option (right to buy) | 75,000 | 6.33 | 474.8K | 75,000 | — | ↗ |
| 2017-01-04 | Magnani John L. | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 75,000 | 6.33 | 474.8K | 75,000 | — | ↗ |
| 2017-01-04 | King Rachel K. | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 175,000 | 6.33 | 1.11M | 175,000 | — | ↗ |
| 2017-01-04 | Hahn Brian M. | Officer | A-Award | A | Employee Stock Option (right to buy) | 65,000 | 6.33 | 411.5K | 65,000 | — | ↗ |
| 2016-12-20 | JUNIUS DANIEL M | Director | P-Purchase | A | Common Stock | 5,000 | 6.01 | 30.1K | 5,000 | — | ↗ |
| 2016-10-03 | Thackray Helen M. | Officer | S-Sale | D | Common Stock | 100 | 7.01 | 701.00 | 156,615 | — | ↗ |
| 2016-07-20 | Thackray Helen M. | Officer | S-Sale | D | Common Stock | 2,000 | 8.00 | 16.0K | 160,615 | — | ↗ |
| 2016-07-06 | Thackray Helen M. | Officer | S-Sale | D | Common Stock | 6,796 | 6.68 | 45.4K | 162,615 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-36.5K
Shares Outstanding
27.57M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2023 | Harout Semerjian -President and Chief Executive Officer | 638.4K | 100.0K | — | 1.26M | 376.9K | 10.8K | 2.39M | 52.87% | ↗ |
| 2 | 2023 | Brian Hahn -Chief Financial Officer and Senior Vice President | 461.0K | 154.7K | — | 477.8K | 196.0K | 10.4K | 1.30M | 36.76% | ↗ |
| 3 | 2023 | Edwin Rock, M.D. -Chief Medical Officer and Senior Vice President | 466.6K | — | — | 474.9K | 198.8K | 12.0K | 1.15M | 41.21% | ↗ |
| 4 | 2022 | Harout Semerjian -President and Chief Executive Officer | 614.1K | 100.0K | — | 338.8K | 372.6K | 9.5K | 1.43M | 23.61% | ↗ |
| 5 | 2022 | Brian Hahn -Chief Financial Officer and Senior Vice President | 443.5K | 103.1K | — | 169.9K | 193.0K | 8.7K | 918.2K | 18.51% | ↗ |
| 6 | 2022 | Armand Girard -Former Chief Business Officer and Senior Vice President | 412.8K | 96.0K | — | 153.9K | — | 91.5K | 754.3K | 20.41% | ↗ |
| 7 | 2021 | Harout Semerjian -President and Chief Executive Officer | 243.7K | 100.0K | — | 2.39M | 129.5K | 8.7K | 2.88M | 83.24% | ↗ |
| 8 | 2021 | Rachel King -Former President and Chief Executive Officer | 511.1K | — | 366.7K | 521.0K | — | 22.0K | 1.42M | 62.47% | ↗ |
| 9 | 2021 | Brian Hahn -Senior Vice President and Chief Financial Officer | 428.6K | 202.5K | 131.4K | 186.7K | 164.6K | 8.7K | 1.12M | 28.34% | ↗ |
| 10 | 2021 | Brian Hahn -Chief Financial Officer and Senior Vice President | 428.6K | 202.5K | 131.4K | 186.7K | 164.6K | 8.7K | 1.12M | 28.34% | ↗ |
| 11 | 2021 | John Magnani, Ph.D. -Senior Vice President of Research and Chief Scientific Officer | 428.4K | 202.4K | 131.4K | 186.7K | 164.5K | 7.9K | 1.12M | 28.37% | ↗ |
| 12 | 2020 | Rachel King -Former President and Chief Executive Officer | 576.1K | 279.7K | — | 1.19M | 332.7K | 8.6K | 2.39M | 49.85% | ↗ |
| 13 | 2020 | Rachel King President and Chief Executive Officer | 576.1K | 279.7K | — | 1.19M | 332.7K | 8.6K | 2.39M | 49.85% | ↗ |
| 14 | 2020 | Nassim Usman, Ph.D. President and Chief Executive Officer | 574.2K | — | — | 640.4K | 178.8K | 16.2K | 1.41M | 45.43% | ↗ |
| 15 | 2020 | Helen Thackray 1 Senior Vice President of Clinical Development and Chief Medical Officer 1 Dr. Thackray resigned effective March 19, 2021 | 450.5K | 218.7K | — | 409.2K | 207.2K | 8.7K | 1.29M | 31.61% | ↗ |
| 16 | 2020 | Brian Hahn Senior Vice President and Chief Financial Officer | 417.2K | 202.5K | — | 409.2K | 175.2K | 8.7K | 1.21M | 33.74% | ↗ |
| 17 | 2020 | Brian Hahn -Senior Vice President and Chief Financial Officer | 417.2K | 202.5K | — | 409.2K | 175.2K | 8.7K | 1.21M | 33.74% | ↗ |
| 18 | 2020 | Clinton Musil Chief Financial Officer | 197.7K | — | — | 696.1K | 66.5K | 6.6K | 966.9K | 72.00% | ↗ |
| 19 | 2020 | Howard Levy, M.B.B.Ch., Ph.D., M.M.M Chief Medical Officer | 450.3K | — | — | 249.7K | 112.3K | 14.3K | 826.7K | 30.20% | ↗ |
| 20 | 2019 | Rachel King President and Chief Executive Officer | 559.3K | — | — | 1.84M | 276.9K | 8.5K | 2.69M | 68.59% | ↗ |
| 21 | 2019 | Helen Thackray 1 Senior Vice President of Clinical Development and Chief Medical Officer 1 Dr. Thackray resigned effective March 19, 2021 | 437.4K | — | — | 696.0K | 158.8K | 8.5K | 1.30M | 53.51% | ↗ |
| 22 | 2019 | Nassim Usman, Ph.D. President and Chief Executive Officer | 524.8K | — | — | 455.4K | 211.6K | 7.1K | 1.20M | 37.98% | ↗ |
| 23 | 2019 | Brian Hahn Senior Vice President and Chief Financial Officer | 405.0K | — | — | 626.4K | 148.2K | 8.5K | 1.19M | 52.72% | ↗ |
| 24 | 2019 | Howard Levy, M.B.B.Ch., Ph.D., M.M.M Chief Medical Officer | 419.5K | — | — | 199.3K | 110.0K | 4.2K | 733.0K | 27.19% | ↗ |
| 25 | 2019 | Fletcher Payne Chief Financial Officer | 252.8K | — | — | 216.4K | — | 2.0K | 471.2K | 45.92% | ↗ |
| 26 | 2019 | Helen Thackray, M.D. Chief Medical Officer | — | — | — | — | — | — | — | — | ↗ |
| 27 | 2019 | John Magnani, Ph.D. Chief Scientific Officer | — | — | — | — | — | — | — | — | ↗ |
| 28 | 2018 | Nassim Usman, Ph.D. President and Chief Executive Officer | 480.8K | 240.4K | — | 1.72M | — | 5.4K | 2.44M | 70.25% | ↗ |
| 29 | 2018 | Howard Levy, M.B.B.Ch., Ph.D., M.M.M. Chief Medical Officer | 397.8K | 139.2K | — | 658.5K | — | 3.3K | 1.20M | 54.92% | ↗ |
| 30 | 2018 | Fletcher Payne Chief Financial Officer | 345.3K | 120.9K | — | 501.2K | — | 2.1K | 969.5K | 51.70% | ↗ |
| 31 | 2018 | Brian Hahn Chief Financial Officer and Senior Vice President | — | — | — | — | — | — | — | — | ↗ |
| 32 | 2018 | John Magnani, Ph.D. Chief Scientific Officer | — | — | — | — | — | — | — | — | ↗ |
| 33 | 2018 | Helen Thackray, M.D. Chief Medical Officer | — | — | — | — | — | — | — | — | ↗ |
| 34 | 2018 | Rachel King President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 35 | 2017 | Nassim Usman, Ph.D. President and Chief Executive Officer | 464.1K | 303.4K | — | 1.06M | — | 5.4K | 1.84M | 57.89% | ↗ |
| 36 | 2017 | Nassim Usman, Ph.D. President and Chief | 464.1K | 303.4K | — | 1.06M | — | 5.4K | 1.84M | 57.89% | ↗ |
| 37 | 2017 | Howard Levy, M.B.B.Ch., Ph.D., M.M.M. Chief Medical Officer | 386.3K | 175.7K | — | 366.9K | — | 3.3K | 932.2K | 39.36% | ↗ |
| 38 | 2017 | Fletcher Payne Chief Financial Officer | 335.2K | 152.5K | — | 289.4K | — | 2.1K | 779.2K | 37.13% | ↗ |
| 39 | 2017 | Helen M. Thackray, M.D. Chief Medical Officer | — | — | — | — | — | — | — | — | ↗ |
| 40 | 2017 | Rachel K. King President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 41 | 2017 | Brian M. Hahn Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 42 | 2017 | John L. Magnani, Ph.D. Chief Scientific Officer | — | — | — | — | — | — | — | — | ↗ |
| 43 | 2017 | Rachel King President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 44 | 2017 | John Magnani, Ph.D. Chief Scientific Officer | — | — | — | — | — | — | — | — | ↗ |
| 45 | 2017 | Helen Thackray, M.D. Chief Medical Officer | — | — | — | — | — | — | — | — | ↗ |
| 46 | 2017 | Brian Hahn Chief Financial Officer and Senior Vice President | — | — | — | — | — | — | — | — | ↗ |
| 47 | 2016 | Edwin L. Madison, Ph.D. Former Chief Scientific Officer | 279.4K | — | — | 11.0K | — | 405.5K | 695.8K | 1.58% | ↗ |
| 48 | 2016 | Nassim Usman, Ph.D. President and Chief | 453.2K | 113.3K | — | — | — | 3.1K | 569.6K | 0.00% | ↗ |
| 49 | 2016 | Nassim Usman, Ph.D. President and Chief Executive Officer | 453.2K | 113.3K | — | — | — | 3.1K | 569.6K | 0.00% | ↗ |
| 50 | 2016 | Howard Levy, M.B.B.Ch., Ph.D., M.M.M. Chief Medical Officer | 265.6K | 46.5K | — | 100.1K | — | 1.9K | 414.1K | 24.16% | ↗ |
| 51 | 2016 | Fletcher Payne Chief Financial Officer | 325.5K | 57.0K | — | — | — | 1.2K | 383.7K | 0.00% | ↗ |
| 52 | 2016 | Brian M. Hahn Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 53 | 2016 | Helen M. Thackray, M.D. Chief Medical Officer | — | — | — | — | — | — | — | — | ↗ |
| 54 | 2016 | John L. Magnani, Ph.D. Chief Scientific Officer | — | — | — | — | — | — | — | — | ↗ |
| 55 | 2016 | Rachel K. King President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 56 | 2015 | Nassim Usman, Ph.D. President and Chief Executive Officer | 413.3K | 169.4K | — | 1.78M | — | 4.4K | 2.37M | 75.20% | ↗ |
| 57 | 2015 | Stephen A. Hill Former President and Chief Executive Officer | 328.1K | — | — | 66.0K | — | 1.45M | 1.84M | 3.58% | ↗ |
| 58 | 2015 | Edwin L. Madison, Ph.D. Chief Scientific Officer | 333.3K | 94.3K | — | 1.00M | — | — | 1.43M | 70.09% | ↗ |
| 59 | 2015 | Edwin L. Madison, Ph.D. Former Chief Scientific Officer | 333.3K | 94.3K | — | 1.00M | — | — | 1.43M | 70.09% | ↗ |
| 60 | 2015 | Fletcher Payne Chief Financial Officer | 230.3K | 85.2K | — | 600.6K | — | — | 916.1K | 65.56% | ↗ |
| 61 | 2015 | Fletcher Payne Chief Financial Officer | 230.3K | 85.2K | — | 600.6K | — | — | 916.1K | 65.56% | ↗ |
| 62 | 2015 | Patrick C. Rock Former Senior Vice President, General Counsel and Secretary | 207.4K | — | — | — | — | 564.4K | 771.8K | 0.00% | ↗ |
| 63 | 2015 | Mauri K. Hodges Former Vice President, Finance and Administration, Chief Financial Officer, Treasurer | 225.0K | — | — | — | — | 479.6K | 704.6K | 0.00% | ↗ |
| 64 | 2015 | Scott N. Cullison Former Vice President, Business Development | 104.2K | — | — | — | — | 475.3K | 579.4K | 0.00% | ↗ |
| 65 | 2015 | Brian Hahn Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 66 | 2015 | Rachel K. King President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 67 | 2015 | John L. Magnani, Ph.D. Chief Scientific Officer | — | — | — | — | — | — | — | — | ↗ |
| 68 | 2015 | Helen M. Thackray, M.D. Chief Medical Officer | — | — | — | — | — | — | — | — | ↗ |
| 69 | 2015 | Brian M. Hahn Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 70 | 2015 | Rachel King President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 71 | 2015 | Helen Thackray, M.D. Chief Medical Officer | — | — | — | — | — | — | — | — | ↗ |
| 72 | 2015 | John Magnani, Ph.D. Chief Scientific Officer | — | — | — | — | — | — | — | — | ↗ |
| 73 | 2015 | Howard Levy, M.B.B.Ch., Ph.D., M.M.M. Chief Medical Officer | — | — | — | — | — | — | — | — | ↗ |
| 74 | 2014 | Stephen A. Hill Former President and Chief Executive Officer | 515.0K | 129.5K | 339.5K | 682.5K | — | 10.8K | 1.68M | 60.93% | ↗ |
| 75 | 2014 | Alan A. Musso Former Senior Vice President, Finance and Administration, Chief Financial Officer, Treasurer and Assistant Secretary | 313.8K | — | 106.7K | 214.5K | — | 25.7K | 660.7K | 48.61% | ↗ |
| 76 | 2014 | Patrick C. Rock Former Senior Vice President, General Counsel and Secretary | 325.5K | 60.3K | 87.3K | 175.5K | — | 10.4K | 658.9K | 39.88% | ↗ |
| 77 | 2014 | Steven M. Toler | 265.2K | 40.1K | 87.3K | 175.5K | — | 10.4K | 578.5K | 45.43% | ↗ |
| 78 | 2014 | Mauri K. Hodges Former Vice President, Finance and Administration, Chief Financial Officer, Treasurer | 258.5K | 35.4K | 77.6K | 156.0K | — | 10.4K | 538.0K | 43.42% | ↗ |
| 79 | 2014 | Mauri K. Hodges Former Vice President, Finance and Administration, Chief Financial Officer, Treasurer | 258.5K | 35.4K | 77.6K | 156.0K | — | 10.4K | 538.0K | 43.42% | ↗ |
| 80 | 2014 | Scott N. Cullison Former Vice President, Business Development | 210.0K | 28.9K | 77.6K | 156.0K | — | 10.4K | 482.9K | 48.38% | ↗ |
| 81 | 2014 | Scott N. Cullison Former Vice President, Business Development | 210.0K | 28.9K | 77.6K | 156.0K | — | 10.4K | 482.9K | 48.38% | ↗ |
| 82 | 2014 | Nassim Usman, Ph.D. President and Chief Executive Officer | 400.0K | 50.0K | — | — | — | 2.2K | 452.2K | 0.00% | ↗ |
| 83 | 2014 | Edwin L. Madison, Ph.D. Chief Scientific Officer | 325.0K | 25.0K | — | — | — | — | 350.0K | 0.00% | ↗ |
| 84 | 2014 | Helen Thackray, M.D. Chief Medical Officer | — | — | — | — | — | — | — | — | ↗ |
| 85 | 2014 | Rachel King President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 86 | 2014 | John Magnani, Ph.D. Chief Scientific Officer | — | — | — | — | — | — | — | — | ↗ |
| 87 | 2014 | Brian Hahn Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 88 | 2013 | Nassim Usman, Ph.D. President and Chief Executive Officer | 400.0K | — | — | 331.4K | — | 4.3K | 735.7K | 45.05% | ↗ |
| 89 | 2013 | Alan A. Musso Senior Vice President, Finance and Administration, Chief Financial Officer, Treasurer and Assistant Secretary | 343.4K | 156.8K | — | 205.3K | — | 10.2K | 715.7K | 28.68% | ↗ |
| 90 | 2013 | Alan A. Musso Former Senior Vice President, Finance and Administration, Chief Financial Officer, Treasurer and Assistant Secretary | 343.4K | 156.8K | — | 205.3K | — | 10.2K | 715.7K | 28.68% | ↗ |
| 91 | 2013 | Stephen A. Hill Former President and Chief Executive Officer | 500.0K | 187.5K | — | — | — | 11.9K | 699.4K | 0.00% | ↗ |
| 92 | 2013 | Stephen A. Hill President and Chief Executive Officer | 500.0K | 187.5K | — | — | — | 11.9K | 699.4K | 0.00% | ↗ |
| 93 | 2013 | David A. Hosford Vice President, Clinical | 283.3K | 113.7K | — | 142.1K | — | 10.2K | 549.3K | 25.87% | ↗ |
| 94 | 2013 | Peter A. Zorn Former Senior Vice President, Legal Affairs, General Counsel and Secretary | 238.0K | 61.6K | — | 205.3K | — | 39.5K | 544.4K | 37.71% | ↗ |
| 95 | 2013 | Patrick C. Rock Former Senior Vice President, General Counsel and Secretary | 111.4K | 29.2K | — | 365.4K | — | 13.8K | 519.8K | 70.29% | ↗ |
| 96 | 2013 | Patrick C. Rock Former Senior Vice President, General Counsel and Secretary | 111.4K | 29.2K | — | 365.4K | — | 13.8K | 519.8K | 70.29% | ↗ |
| 97 | 2013 | Edwin L. Madison, Ph.D. Chief Scientific Officer | 325.0K | — | — | 165.7K | — | — | 490.7K | 33.77% | ↗ |
| 98 | 2013 | Rachel King President and Chief Executive Officer | 365.7K | — | — | — | 89.6K | — | 455.2K | 0.00% | ↗ |
| 99 | 2013 | Helen Thackray, M.D. Chief Medical Officer | 314.2K | 23.6K | — | — | 55.0K | — | 392.8K | 0.00% | ↗ |
| 100 | 2013 | John Magnani, Ph.D. Chief Scientific Officer | 293.6K | — | — | — | 51.4K | — | 344.9K | 0.00% | ↗ |
| 101 | 2013 | Brian Hahn Chief Financial Officer | 216.7K | — | — | — | 43.8K | — | 260.4K | 0.00% | ↗ |
| 102 | 2012 | Stephen A. Hill President and Chief Executive Officer | 41.7K | — | — | 1.18M | — | 1.7K | 1.22M | 96.46% | ↗ |
| 103 | 2012 | Stephen A. Hill Former President and Chief Executive Officer | 41.7K | — | — | 1.18M | — | 1.7K | 1.22M | 96.46% | ↗ |
| 104 | 2012 | Stephen A. Hill President and Chief Executive Officer | 41.7K | — | — | 1.18M | — | 1.7K | 1.22M | 96.46% | ↗ |
| 105 | 2012 | Jeffrey P. Brennan Former Senior Vice President, Business and Commercial Development and Chief Business Officer | 339.3K | 52.8K | — | 302.0K | 5.9K | 10.0K | 710.0K | 42.53% | ↗ |
| 106 | 2012 | Alan A. Musso Former Senior Vice President, Finance and Administration, Chief Financial Officer, Treasurer and Assistant Secretary | 333.4K | 52.5K | — | 302.0K | 5.8K | 10.0K | 703.7K | 42.91% | ↗ |
| 107 | 2012 | Alan A. Musso Senior Vice President, Finance and Administration, Chief Financial Officer, Treasurer and Assistant Secretary | 333.4K | 52.5K | — | 302.0K | 5.8K | 10.0K | 703.7K | 42.91% | ↗ |
| 108 | 2012 | Peter A. Zorn Senior Vice President, Legal Affairs, General Counsel and Secretary | 308.1K | 51.2K | — | 302.0K | 5.4K | 10.0K | 676.6K | 44.63% | ↗ |
| 109 | 2012 | Peter A. Zorn Former Senior Vice President, Legal Affairs, General Counsel and Secretary | 308.1K | 51.2K | — | 302.0K | 5.4K | 10.0K | 676.6K | 44.63% | ↗ |
| 110 | 2012 | J. Donald deBethizy Former President and Chief Executive Officer | 204.7K | — | — | 407.7K | — | 43.3K | 655.7K | 62.18% | ↗ |
| 111 | 2012 | David A. Hosford Vice President, Clinical | 270.2K | 10.1K | — | 226.5K | 3.4K | 10.0K | 520.2K | 43.54% | ↗ |
| 112 | 2012 | David A. Hosford Vice President, Clinical | 270.2K | 10.1K | — | 226.5K | 3.4K | 10.0K | 520.2K | 43.54% | ↗ |
| 113 | 2012 | Mark Skaletsky | 180.0K | — | — | 158.5K | — | 52.5K | 391.0K | 40.53% | ↗ |
| 114 | 2011 | J. Donald deBethizy President and Chief Executive Officer | 485.7K | — | — | 1.70M | — | 9.8K | 2.19M | 77.38% | ↗ |
| 115 | 2011 | J. Donald deBethizy Former President and Chief Executive Officer | 485.7K | — | — | 1.70M | — | 9.8K | 2.19M | 77.38% | ↗ |
| 116 | 2011 | Geoffrey C. Dunbar Senior Vice President, Clinical Development and Regulatory Affairs and Chief Medical Officer | 351.6K | — | — | 896.2K | — | 9.8K | 1.26M | 71.26% | ↗ |
| 117 | 2011 | Jeffrey P. Brennan Former Senior Vice President, Business and Commercial Development and Chief Business Officer | 334.5K | — | — | 807.4K | — | 9.8K | 1.15M | 70.10% | ↗ |
| 118 | 2011 | Jeffrey P. Brennan Former Senior Vice President, Business and Commercial Development and Chief Business Officer | 334.5K | — | — | 807.4K | — | 9.8K | 1.15M | 70.10% | ↗ |
| 119 | 2011 | Alan A. Musso Senior Vice President, Finance and Administration, Chief Financial Officer, Treasurer and Assistant Secretary | 328.4K | — | — | 807.4K | — | 9.8K | 1.15M | 70.48% | ↗ |
| 120 | 2011 | Alan A. Musso Senior Vice President, Finance and Administration, Chief Financial Officer, Treasurer and Assistant Secretary | 328.4K | — | — | 807.4K | — | 9.8K | 1.15M | 70.48% | ↗ |
| 121 | 2011 | Peter A. Zorn Former Senior Vice President, Legal Affairs, General Counsel and Secretary | 303.4K | — | — | 807.4K | — | 9.8K | 1.12M | 72.05% | ↗ |
| 122 | 2011 | Peter A. Zorn Senior Vice President, Legal Affairs, General Counsel and Secretary | 303.4K | — | — | 807.4K | — | 9.8K | 1.12M | 72.05% | ↗ |
| 123 | 2010 | J. Donald deBethizy President and Chief Executive Officer | 442.2K | 27.0K | — | 934.6K | 132.7K | 9.8K | 1.55M | 60.44% | ↗ |
| 124 | 2010 | J. Donald deBethizy Former President and Chief Executive Officer | 442.2K | 27.0K | — | 934.6K | 132.7K | 9.8K | 1.55M | 60.44% | ↗ |
| 125 | 2010 | Geoffrey C. Dunbar Senior Vice President, Clinical Development and Regulatory Affairs and Chief Medical Officer | 321.3K | 11.8K | — | 667.6K | 57.8K | 9.8K | 1.07M | 62.49% | ↗ |
| 126 | 2010 | Jeffrey P. Brennan Former Senior Vice President, Business and Commercial Development and Chief Business Officer | 300.1K | 11.0K | — | 667.6K | 54.0K | 9.8K | 1.04M | 64.04% | ↗ |
| 127 | 2010 | Jeffrey P. Brennan Senior Vice President, Business and Commercial Development and Chief Business Officer | 300.1K | 11.0K | — | 667.6K | 54.0K | 9.8K | 1.04M | 64.04% | ↗ |
| 128 | 2010 | Alan A. Musso Senior Vice President, Finance and Administration, Chief Financial Officer, Treasurer and Assistant Secretary | 293.2K | 10.7K | — | 667.6K | 52.8K | 9.8K | 1.03M | 64.56% | ↗ |
| 129 | 2010 | Peter A. Zorn Senior Vice President, Legal Affairs, General Counsel and Secretary | 270.6K | 9.9K | — | 667.6K | 48.7K | 9.8K | 1.01M | 66.32% | ↗ |
| 130 | 2009 | J. Donald deBethizy President and Chief Executive Officer | 384.5K | 143.3K | — | 125.5K | 177.4K | 14.7K | 845.4K | 14.85% | ↗ |
| 131 | 2009 | Geoffrey C. Dunbar Senior Vice President, Clinical Development and Regulatory Affairs and Chief Medical Officer | 292.1K | 83.7K | — | 88.8K | 89.8K | 14.7K | 569.2K | 15.61% | ↗ |
| 132 | 2009 | Jeffrey P. Brennan Senior Vice President, Business and Commercial Development and Chief Business Officer | 276.6K | 85.7K | — | 101.4K | 85.0K | 14.7K | 563.5K | 17.99% | ↗ |
| 133 | 2009 | Alan A. Musso Senior Vice President, Finance and Administration, Chief Financial Officer, Treasurer and Assistant Secretary | 276.6K | 80.7K | — | 101.4K | 85.0K | 14.7K | 558.5K | 18.16% | ↗ |
| 134 | 2009 | Peter A. Zorn Senior Vice President, Legal Affairs, General Counsel and Secretary | 246.0K | 93.5K | — | 88.8K | 75.6K | 14.7K | 518.6K | 17.13% | ↗ |
| 135 | 2008 | J. Donald deBethizy President and Chief Executive Officer | 384.5K | 8.7K | — | 259.8K | 95.2K | 13.8K | 762.0K | 34.10% | ↗ |
| 136 | 2008 | Geoffrey C. Dunbar Vice President, Clinical Development and Regulatory Affairs | 292.1K | 4.4K | — | 154.3K | 48.2K | 13.8K | 512.8K | 30.10% | ↗ |
| 137 | 2008 | J. Donald deBethizy President and Chief Executive Officer | 384.5K | 8.7K | — | — | 95.2K | 13.8K | 502.1K | 0.00% | ↗ |
| 138 | 2008 | Jeffrey P. Brennan Vice President, Business and Commercial Development | 276.6K | 4.1K | — | 141.6K | 45.6K | 13.8K | 481.7K | 29.39% | ↗ |
| 139 | 2008 | Alan A. Musso Vice President, Chief Financial Officer, Treasurer and Assistant Secretary | 276.6K | 4.1K | — | 127.9K | 45.6K | 13.8K | 468.1K | 27.33% | ↗ |
| 140 | 2008 | Merouane Bencherif Vice President, Preclinical Research | 230.1K | 3.5K | — | 153.4K | 38.0K | 13.8K | 438.6K | 34.97% | ↗ |
| 141 | 2008 | Geoffrey C. Dunbar Senior Vice President, Clinical Development and Regulatory Affairs and Chief Medical Officer | 292.1K | 4.4K | — | — | 48.2K | 13.8K | 358.5K | 0.00% | ↗ |
| 142 | 2008 | Alan A. Musso Senior Vice President, Finance and Administration, Chief Financial Officer, Treasurer and Assistant Secretary | 276.6K | 4.1K | — | — | 45.6K | 13.8K | 340.2K | 0.00% | ↗ |
| 143 | 2008 | Jeffrey P. Brennan Senior Vice President, Business and Commercial Development and Chief Business Officer | 276.6K | 4.1K | — | — | 45.6K | 13.8K | 340.2K | 0.00% | ↗ |
| 144 | 2007 | J. Donald deBethizy President and Chief Executive Officer | 348.4K | 10.5K | — | 320.5K | 205.6K | 13.5K | 898.5K | 35.68% | ↗ |
| 145 | 2007 | Geoffrey C. Dunbar Senior Vice President, Clinical Development and Regulatory Affairs | 282.1K | 6.3K | — | 331.4K | 124.8K | 13.5K | 758.1K | 43.71% | ↗ |
| 146 | 2007 | Jeffrey P. Brennan Senior Vice President, Business and Commercial Development and Chief Business Officer Peter A. Zorn Senior Vice President, Legal Affairs, General Counsel and Secretary | 257.7K | 5.8K | — | 223.3K | 114.0K | 13.5K | 614.3K | 36.35% | ↗ |
| 147 | 2007 | Alan A. Musso Senior Vice President, Finance and Administration, Chief Financial Officer, Treasurer and Assistant Secretary | 257.0K | 5.8K | — | 216.6K | 113.7K | 13.5K | 606.6K | 35.70% | ↗ |
| 148 | 2007 | J. Donald deBethizy President and Chief Executive Officer | 348.4K | 10.5K | — | 125.5K | 205.6K | 13.5K | 577.9K | 21.72% | ↗ |
| 149 | 2007 | Geoffrey C. Dunbar Vice President, Clinical Development and Regulatory Affairs | 282.1K | 6.3K | — | 109.5K | 124.8K | 13.5K | 536.3K | 20.42% | ↗ |
| 150 | 2007 | Geoffrey C. Dunbar Vice President, Clinical Development and Regulatory Affairs | 282.1K | 6.3K | — | 109.5K | 124.8K | 13.5K | 536.3K | 20.42% | ↗ |
| 151 | 2007 | Jeffrey P. Brennan Vice President, Business and Commercial Development | 257.7K | 5.8K | — | 110.1K | 114.0K | 13.5K | 501.2K | 21.97% | ↗ |
| 152 | 2007 | Jeffrey P. Brennan Vice President, Business and Commercial Development | 257.7K | 5.8K | — | 110.1K | 114.0K | 13.5K | 501.2K | 21.97% | ↗ |
| 153 | 2007 | Alan A. Musso Vice President, Chief Financial Officer, Treasurer and Assistant Secretary | 257.0K | 5.8K | — | 100.9K | 113.7K | 13.5K | 490.9K | 20.55% | ↗ |
| 154 | 2007 | Alan A. Musso Vice President, Chief Financial Officer, Treasurer and Assistant Secretary | 257.0K | 5.8K | — | 100.9K | 113.7K | 13.5K | 490.9K | 20.55% | ↗ |
| 155 | 2007 | Merouane Bencherif Vice President, Preclinical Research | 217.4K | 4.9K | — | 107.5K | 96.2K | 13.5K | 439.4K | 24.46% | ↗ |
| 156 | 2007 | Merouane Bencherif Vice President, Preclinical Research | 217.4K | 4.9K | — | 107.5K | 96.2K | 13.5K | 439.4K | 24.46% | ↗ |
| 157 | 2006 | J. Donald deBethizy President and Chief Executive Officer | 335.0K | 33.5K | — | 244.2K | 180.9K | 13.2K | 806.8K | 30.27% | ↗ |
| 158 | 2006 | J. Donald deBethizy President and Chief Executive Officer | 335.0K | 33.5K | — | 244.2K | 180.9K | 13.2K | 806.8K | 30.27% | ↗ |
| 159 | 2006 | Geoffrey C. Dunbar Vice President, Clinical Development and Regulatory Affairs | 269.6K | 20.2K | — | 71.2K | 109.2K | 13.2K | 483.4K | 14.73% | ↗ |
| 160 | 2006 | Geoffrey C. Dunbar Vice President, Clinical Development and Regulatory Affairs | 269.6K | 20.2K | — | 71.2K | 109.2K | 13.2K | 483.4K | 14.73% | ↗ |
| 161 | 2006 | Alan A. Musso Vice President, Chief Financial Officer, Treasurer and Assistant Secretary | 233.7K | 17.5K | — | 68.6K | 94.7K | 13.2K | 427.7K | 16.03% | ↗ |
| 162 | 2006 | Alan A. Musso Vice President, Chief Financial Officer, Treasurer and Assistant Secretary | 233.7K | 17.5K | — | 68.6K | 94.7K | 13.2K | 427.7K | 16.03% | ↗ |
| 163 | 2006 | Jeffrey P. Brennan Vice President, Business and Commercial Development | 245.7K | 18.4K | — | 44.5K | 99.5K | 13.2K | 421.3K | 10.56% | ↗ |
| 164 | 2006 | Jeffrey P. Brennan Vice President, Business and Commercial Development | 245.7K | 18.4K | — | 44.5K | 99.5K | 13.2K | 421.3K | 10.56% | ↗ |
| 165 | 2006 | Merouane Bencherif Vice President, Preclinical Research | 208.0K | 15.6K | — | 68.8K | 84.2K | 13.2K | 389.8K | 17.65% | ↗ |
| 166 | 2006 | Merouane Bencherif Vice President, Preclinical Research | 208.0K | 15.6K | — | 68.8K | 84.2K | 13.2K | 389.8K | 17.65% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Joshua T. Brumm | Chief Executive Officer & Director | 1M | male |
| Jonathan McNeill | President & Chief Operating Officer | 871.7K | — |
| Ellie Im | Chief Medical Officer | 847.8K | — |
| Jan Pinkas | Chief Scientific Officer | — | — |
| Richard William Scalzo | Chief Financial Officer | — | male |
| Ryan Lynch | Senior Vice President of Finance, Treasurer & Chief Accounting Officer | — | male |
| Tanya Sengupta | Executive VP and Chief of Strategy & Operations | — | female |
| Amy Reilly | Chief Communications Officer | — | female |
| Wenjie Cheng | Senior Vice President of Technical Operations | — | — |
| Barbara H. Bispham | General Counsel & Corporate Secretary | — | female |
| Christopher Doughty | Chief Business Officer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CBIO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
